Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 5, 2010

View Archived Issues

MedImmune reports clinical data on asthma candidates MEDI-563 and MEDI-528

PH-797804 improves lung function in patients with COPD

Preclinical and clinical data reported on neoglycoside ACHN-490

Intranasal XF-73 well tolerated in phase I study

Phase I data support safety of TissueGene-C in osteoarthritis

Plexxikon discloses new inhibitors of protein kinases

Maximum tolerated dose of ARRY-380 established in patients with breast cancer

Achillion begins dosing in phase IIa trial of ACH-1625 in HCV infection

Global marketing rights to Caelyx to transition from Merck & Co. to Janssen

Eisai and Anaeropharma partner to discover Bifidobacterium-delivered anticancer agents

Barcelona researchers claim new apoptosis inducers

Trophos begins clinical development of TRO-40303

Embera NeuroTherapeutics obtains NIDA grant for EMB-001 development

Pierre Fabre Medicament discloses new 11-beta-HSD1 inhibitors

Argenta and Janssen enter into cancer drug discovery agreement

Cortex Pharma regains rights to Ampakine agents for depression and schizophrenia

Merck Serono discovers new lysophospholipid S1P1 receptor antagonists

Cellceutix completes toxicity studies of anticancer agent Kevetrin

SEPS Pharma presents new antifungal agents

CHMP recommends variation to terms of marketing authorization for Invega

AcelRx completes end-of-phase II meeting with FDA on ARX-02 Sufentanil NanoTab

GSK discontinues Simplirix development for genital herpes

Biomarker analysis demonstrates potential of MGN-1703 against cancer

PEGASUS-TIMI 54 trial to evaluate long-term post-ACS efficacy and safety of ticagrelor

GW Pharma begins phase IIa trial of cannabinoids in type 2 diabetes

FDA requests change in tapentadol ER formulation in complete response letter to J&JPRD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...